These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32451974)

  • 1. Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases.
    van Lint JA; Jessurun NT; Hebing RCF; Hoentjen F; Tas SW; Vonkeman HE; van Doorn MBA; Sobels A; Spuls PI; van Puijenbroek EP; Nurmohamed MT; van den Bemt BJF
    Drug Saf; 2020 Sep; 43(9):917-925. PubMed ID: 32451974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-mediated inflammatory disease patients' preferences in adverse drug reaction information regarding biologics.
    Kosse LJ; Weits G; Vonkeman HE; Spuls PI; Van Den Bemt BJF; Tas SW; Hoentjen F; Nurmohamed MT; Van Doorn MBA; Van Puijenbroek EP; Jessurun NT
    Expert Opin Drug Saf; 2020 Aug; 19(8):1049-1054. PubMed ID: 32524887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapy.
    Thomas PWA; Römkens TEH; West RL; Russel MGVM; Jansen JM; van Lint JA; Jessurun NT; Hoentjen F
    United European Gastroenterol J; 2021 Oct; 9(8):919-928. PubMed ID: 34077634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients' perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes.
    Kosse LJ; Weits G; Vonkeman HE; Tas SW; Hoentjen F; Van Doorn MB; Spuls PI; D'Haens GR; Nurmohamed MT; van Puijenbroek EP; Van Den Bemt BJ; Jessurun NT
    Expert Opin Drug Saf; 2021 Dec; 20(12):1565-1572. PubMed ID: 34348543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stakeholders' perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases.
    Kosse LJ; Jessurun NT; Vonkeman HE; Tas SW; Nurmohamed MT; Hoentjen F; van Doorn MBA; van Puijenbroek EP; van den Bemt BJF; de Vries M
    Expert Opin Drug Saf; 2020 Nov; 19(11):1521-1528. PubMed ID: 32730115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases.
    Gosselt HR; van Lint JA; Kosse LJ; Spuls PI; Vonkeman HE; Tas SW; Hoentjen F; Nurmohamed MT; van den Bemt BJF; van Doorn MBA; Jessurun NT
    Expert Opin Drug Saf; 2023; 22(6):501-507. PubMed ID: 36794307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor.
    van Lint JA; Jessurun NT; Tas SW; Vonkeman HE; van Doorn MBA; Hoentjen F; Nurmohamed MT; van Puijenbroek EP; van den Bemt BJF
    BioDrugs; 2023 Jul; 37(4):541-550. PubMed ID: 37010772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of medicines-Pharmacists' knowledge, practice, and attitudes toward pharmacovigilance and adverse drug reactions reporting process.
    Kopciuch D; Zaprutko T; Paczkowska A; Ratajczak P; Zielińska-Tomczak Ł; Kus K; Nowakowska E
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1543-1551. PubMed ID: 31148344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collaboration between patient and pharmacovigilance organizations to gain insight into adults' experiences with drug use and ADRs for the treatment of ADHD.
    Weits G; Härmark L; Hartman J; Kant A
    Expert Opin Drug Saf; 2019 Apr; 18(4):333-337. PubMed ID: 30845849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of longitudinal patient-reported burden of adverse drug reactions attributed to the use of TNF-α inhibitors in inflammatory rheumatic diseases: an observational prospective cohort study.
    König BH; Gosselt HR; van Lint JA; Kosse LJ; van den Bemt BJF; Ten Klooster PM; Vonkeman HE; Jessurun NT
    Expert Opin Drug Saf; 2024 Aug; ():1-6. PubMed ID: 39041288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knowledge, awareness, perception and reporting of experienced adverse drug reactions among outpatients in Nigeria.
    Adisa R; Adeniyi OR; Fakeye TO
    Int J Clin Pharm; 2019 Aug; 41(4):1062-1073. PubMed ID: 31140162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study.
    Roest LH; Kosse LJ; van Lint JA; Gosselt HR; Scholl JHG; van Puijenbroek E; Vonkeman HE; Tas SW; Nurmohamed MT; van den Bemt BJF; Jessurun NT
    Expert Opin Drug Saf; 2023 Mar; 22(3):203-211. PubMed ID: 36036179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors that facilitate reporting of adverse drug reactions by pharmacists in Saudi Arabia.
    Aldryhim AY; Alomair A; Alqhtani M; Mahmoud MA; Alshammari TM; Pont LG; Kamal KM; Aljadhey H; Mekonnen AB; Alwhaibi M; Balkhi B; Alhawassi TM
    Expert Opin Drug Saf; 2019 Aug; 18(8):745-752. PubMed ID: 31232612
    [No Abstract]   [Full Text] [Related]  

  • 15. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
    Awodele O; Aliu R; Ali I; Oni Y; Adeyeye CM
    Pharmacol Res Perspect; 2018 Oct; 6(5):e00427. PubMed ID: 30324768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study.
    de Vries ST; Denig P; Ekhart C; Mol PGM; van Puijenbroek EP
    Drug Saf; 2020 May; 43(5):489-495. PubMed ID: 32048185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse drug reactions associated with the use of biological agents.
    Machado-Alba JE; Jiménez-Morales AL; Moran-Yela YC; Parrado-Fajardo IY; Valladales-Restrepo LF
    PLoS One; 2020; 15(12):e0240276. PubMed ID: 33338057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The burden of adverse drug reactions reported by patients in the Dutch ADR monitor: a proof of concept.
    Quik JM; Gosselt HR; van Lint JA; Kosse LJ; Ten Klooster PM; Vonkeman HE; van den Bemt BJF; Jessurun NT
    Expert Opin Drug Saf; 2024 Jul; ():. PubMed ID: 39049766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of Adverse Drug Reactions Related to Drug Switches in The Netherlands.
    Glerum PJ; Maliepaard M; de Valk V; Scholl JHG; van Hunsel FPAM; van Puijenbroek EP; Burger DM; Neef K
    Clin Transl Sci; 2020 May; 13(3):599-607. PubMed ID: 32052597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current state of biologic pharmacovigilance in the European Union: improvements are needed.
    Felix T; Jordan JB; Akers C; Patel B; Drago D
    Expert Opin Drug Saf; 2019 Mar; 18(3):231-240. PubMed ID: 30714424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.